



A CASE REPORT ON WILSON’S DISEASE: A RARE CLINICAL CONDITION OF COPPER 
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ABSTRACT 
Wilson’s disease is a rare inherited disorder and is characterized by the accumulation of copper in various tissues and also in organs like the liver, 
brain, kidneys and cornea. Symptoms in paediatrics characteristically appear with hepatic involvement. In this case we have discussed about an 
eleven-year-old male child, who was presented to the Paediatric department in a tertiary care hospital with chief complaints of yellowish 
discoloration of eyes, dark coloured urine and high grade fever. Due to the accumulation of copper there were decreased levels of ceruloplasmin and 
there was an increased 24 hour urinary copper, which confirms the Wilson’s disease in this child. Child was treated with Cephalosporin antibiotics, 
vitamins, laxative, and bile acid sequestrants. Child showed gradual improvement in clinical symptoms and got discharged without any further 
event. Quality of evidence was assessed according to the GRADE system. Early diagnosis and management helped to prevent serious complications. 
Keywords: Paediatric, Ceruloplasmin, Copper, Wilson’s disease 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) 
DOI: https://dx.doi.org/10.22159/ijpps.2021v13i8.41707. Journal homepage: https://innovareacademics.in/journals/index.php/ijpps.  
 
INTRODUCTION 
Wilson Disease (WD) is an intermittent autosomal receding disease 
subsequent in a systemic excess of copper. The stated incidence is 30 
per million people [1]. Wilson’s disease occurs due to mutations of 
the ATP7B gene on chromosome 13, which encrypts a copper-
transporting P-type ATPase (ATP7B) that exists in the trans-golgi 
complex of hepatocytes. ATP7B is mainly liable for enrapturing 
copper from intracellular chaperone proteins into the secretory 
pathway, for the both excretion into bile and also for the integration 
into apo-ceruloplasmin for the synthesis of functional ceruloplasmin. 
Wilson’s disease develops due to the build-up of copper in affected 
tissues [2]. Copper is a crucial contented of many metabolic 
enzymes. Usual predictable total body copper is 50-100 mg and 
average daily intake of copper is 2-5 mg. The amount of copper in 
the body is average during birth. Afterwards, it increases 
progressively. Generally, the symptoms initiate between the ages 5 
and 45 y [3]. The main complications of Wilson’s disease include 
brain damage and liver cirrhosis, psychiatric disturbances, i.e., 
depression, suicidal tendencies, and aggressive behaviour motor 
dysfunction and corneal opacities [4]. The simple diagnostic method 
comprises serum ceruloplasmin and 24hour urinary copper 
excretion. Final diagnosis of Wilson disease can be recognized using 
a diagnostic scoring system based on symptoms, biochemical tests 
which assess copper metabolism and molecular analysis of 
mutations in the ATP7B gene. The Grades of Recommendation, 
Assessment, Development and Evaluation (GRADE) 
GRADE system as used European association for the study of the 
liver (EASL) clinical practice guidelines (159) 
system of 
diagnosis is described below. 
High-Quality Further research is very unlikely to change our 
confidence in the estimated effect. 
Moderate Quality Further research is likely to have an important impact 
on our confidence in the estimate effect and may change the estimate. 
Low Quality Further research is likely to have an important impact 
on our confidence in the estimate effect and is likely to change the 
estimate is uncertain. 
Recommendation 
Strong-Factors influencing the strength of recommendation included the 
quality of evidence, presumed patient-important outcomes and costs. 
Weak-Variability in preferences and values, or more certainty, 
higher costs or resource consumption. 
System of recommendation as used in the American Association 
for the study of liver disease (AASLD) practice guidelines (130) 
Class I-Conditions for which there is evidence and general 
agreement that a given procedure or treatment is beneficial, useful 
and effective. 
Class II-Conditions for which there is conflicting and/or a divergence of 
opinion about the usefulness/efficacy of a procedure or treatment. 
Class IIa-Weight of evidence/opinion is in favour of usefulness/efficacy. 
Class IIb-Usefulness/efficacy is less well established. 
Level of evidence 
Level A-Data derived from multiple randomized clinical trials or 
meta-analyses 
Level B-Data derived from a single randomized trial, or 
nonrandomized studies. 
Level C-Only consensus opinion of experts, case studies. 
Here we discussed about a case of Wilsons disease, which was 
diagnosed on an 11 y old male child with ceruloplasmin and 24hr 
urinary copper levels. 
Case presentation 
An 11yrs old male child was presented in a tertiary care hospital on 
27/11/2019 with chief complaints of (C/O) yellowish discoloration 
of eyes, passing of yellow coloured urine since last two months, high 
grade continuous acute onset of fever since 4 d with no relief by 
medication. Fever was not associated with chills and sweating. 
Complaint of itching sensation since 4 d was also noted. On clinical 
examination (O/E) his vitals were found to be stable with a slight 
increase of temperature (100 ° F). The past history of the patient 
revealed that he was passing yellow coloured urine since past two 
months and discolouration of eyes. History of patient’s present 
illness indicated icterus positive, which enumerate conjugated 
jaundice. His past medical history discloses decreased appetite and 
he was on Tab. Cefixime, Syp. Liv-52 and Syp. Lactulose since one 
month. He was treated with Syp. Folic acid, Syp. Paracetamol 250 
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and Syp. Multivitamin for 10 d after consultation with another 
doctor. Then the family consulted a local registered medical 
practitioner and he was given herbal medication once in a week for 
3 w, which was to be mixed in curd and taken. He developed itching 
and it got subsided by itself. 
Upon admission child was prescribed with:  
Rx 
1. Inj. Hepatic drip 100 ml in 400 ml NS  
2. IVF. Dextrose 10% 
3. Inj. Potassium chloride 5 ml, Calcium Gluconate 5 ml and multi 
Vitamin 2 ml @ 70 ml/h 
4. Inj. Vitamin K 5 mg IV OD 
5. Inj. Cefotaxime 1.5 gm IV BID 
6. Inj. Ranitidine 50 mg IV BID 
7. Syp. Lactulose 7 ml PO QID 
8. Tab. Ursodeoxycholic acid 50 mg PO TID 
9. Cap. Vitamin A and D PO Once in a Week 
10. Cap. Vitamin E PO OD 
11. Lab findings:  
His lab report findings are described in table 1. 
 
Table 1: Parameters with observed values and normal range 
Complete blood picture (28/11/19) Observed values Normal range 
Haemoglobin 10.8 12-15 mg/dl 
RBC 3.93 3.8-4.8 mln/cumm 
WBC 8.40 4-11 Th. cells/cumm 
Platelets 392 150-400L/cumm 
Neutrophils 03 40-80% 
Lymphocytes 4.15 20-40% 
Monocytes 0.58 2-10% 
Eosinophils 0.64 0-6% 
Basophils 0.01 0-2% 
Serum Electrolytes (28/11/19) Observed values Normal range 
Sodium 138 135-150mEq/l 
Potassium 4.2 3.5-5mEq//l 
Chloride 102 96-106mEq/l 
Renal function test and Liver function test (28/11/19) Observed values Normal range 
Total Serum Bilirubin 3.81 0.2-1 mg% * 
SGPT 198.6 7-56U/l * 
Alkaline Phosphate 95.9 42-362U/l 
Serum Creatinine 0.35 0.6-1.2 mg/dl * 
Blood Urea 10.13 15-40 mg/dl * 
APTT 30.3 30-40 Se 
Prothrombin Time 14.0 11.0-12.5 Sec * 
International Normalized Ratio 1.17 0.9-1.1 sec 
Ceruloplasmin (30/12/19) 08 20-35 mg/dl ** 
24h Urinary Copper (30/11/19) 293 20-50µg ** 
Note: *-Indicates abnormal values (higher or lower than normal values) 
**-Indicates highly abnormal values (confirmatory diagnostic values) 
Ultrasound (3/11/19) Impression: Grade–I Fatty infiltration of the liver 
Genetic Analysis (2/12/19) Genetic analysis was found to be negative for Wilson’s disease. 
 
Table 2: Conformational diagnosis describes about the diagnosis 
Tests Values observed Normal value 
24hr Urinary Copper 293 20-50µg 
S. Ceruloplasmin 08 20-35 mg/dl 
With various lab tests and other assessment criteria, the patient was diagnosed as Wilson’s disease and his prescription throughout the admission 
period are explained below. 
 
Treatment 
Day-2 (28/11/19)  
1. IVF Hepatic drip 70 ml/hr 
2. Inj. Vitamin K 5 mg IV STAT 
3. Syp. Lactulose 7 ml P/O QID  
4. Tab. Ursodeoxycholic acid 150 mg P/O TID  
5. Vitamin A and D 1 tab P/O OD 
6. Vitamin E 1 tab P/O OD 
7. Inj. Cefotaxime 1.5 gm IV BID 
8. Inj. Ranitidine 50 mg IV BID 
He was referred to an ophthalmologist and diagnosed as papillar 
positive; evidence of Kayser-Fleischer ring (fig. 1) 
 
 
Fig. 1: Image of kayser-fleischer ring 
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Day-3 (29/11/19) 
He was referred to the pathologist to do hemograph with red count 
and haemoglobin levels were slightly less (10.8 gm/dl) and 
continued the same treatment. 
Day–4 (30/11/19) 
Continued the same treatment and advised for 24hr urinary copper 
test. 
Day–5 (1/12/19) 
There were no fresh complaints and IVF hepatic drip was stopped. 
Day–6 (2/12/19) 
The child was active and the same treatment was given and Inj. 
Cefotaxime was stopped. 
Day–7 (3/12/19) 
Same treatment was continued  
Day–8 (4/11/19) 
Same treatment was continued and 24hr urinary copper level was 
found to be 16.5 µg/h. 
On Day–9 (5/12/19)  
Patient was found to fit to discharge and Kayser-Flesicher ring in 
eyes was completely diminished (fig.2) with the following discharge 
medicine and advised to come for review after 2 w. 
 
 
Fig. 2: Image after child recovery 
 
Discharge medication:  
Rx 
Tab. Ursodeoxycholic acid 150 mg PO BD 
Tab. B complex PO OD 
Vitamin A and D PO OD 
Vitamin E PO OD 
DISCUSSION 
Here we present the Case study of an 11 y old child with Wilson’s 
disease. The patient's past history and present history upon 
admission was evaluated clinically and Provisional and 
Confirmational diagnosis enumerated. Clinical lab findings were a 
guide to start therapeutic regimen and patient improved with time. 
Here we present our role as a Clinical Pharmacist in evaluating the 
Case further with established standard guidelines. Table 5 and table 
6 depict the Ferenci Score and diagnostic approach of the Case. 
Table 3: Stepwise approach to diagnose Wilson’s disease 
 Diagnostic approach to Wilson’s Disease  
1. Clinical evaluation for Hepatosplenomegaly, ascites, K-F ring. 
2. Liver tests-ALT/AST, Bilirubin total/direct, INR. 
3. Biochemical tests of copper metabolism-serum ceruloplasmin, 
24h urinary copper. 
Molecular testing  
(Common mutations, whole  
gene sequencing) 
Liver copper 
(If molecular testing inconclusive or 
not available) 
  
Table 4: Diagnostic score in Wilson’s disease 
Score -1 0 1 
Kayser-Fleisher rings - - Present 
Neuropsychiatric symptoms - Absent - 
Liver copper quantitative Normal - - 
Urinary copper - - Present 
Serum Ceruloplasmin - - Present 
 
Table 5: Represent diagnostic score of Wilson’s disease 
0-1 Unlikely 2-3 Probable 4 or more highly likely 
 
Our assessment shows a score of 2-3showing an outcome of 
Probable. Additionally, Quality of evidence was assessed according 
to the GRADE system which enumerated the following parameters 
viz., Evidence: –Moderate quality, Recommendation–Strong, 
Classification–Class IIa, Level of Evidence–Level C. Patient’s health 
condition improved with the therapeutic intervention.  
Maintenance of proper diet al. so plays a vital role along with 
treatment. Generally, the patient was advised to avoid eating foods 
containing high copper amounts, such as chocolate, nuts, 
mushrooms, legumes and shellfish (lobster) and avoid drinking 
water from atypical sources like well water and instead it should be 
replaced with purified water. Early diagnosis and treatment helped 
in reducing symptoms. The patient’s condition improved and vitals 
were normal. The urinary copper level came to normal. Proper 
medication care, low copper diet should be taken in order to show a 
reduction in mortality 
CONCLUSION 
Based on this Case study and our findings we conclude that, even 
though the case was treated appropriately and discharged 
accordingly, a further recommendation of an extensive investigation 
of all clinical parameters would be more appropriate in order to 
establish a strong Quality of evidence by the GRADE system. This 
would empower Clinicians to establish research findings correlating 
Clinical evidence with outcomes. 
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ABBREVIATIONS 
GRADE- The grades of recommendation, assessment, development 
and evaluation, EASL- European association for the study of the 
liver, AASLD- The American association for the study of liver disease, 
Syp- Syrup, Tab – Tablet, IVF-  Intravenous fluids, NS- Normal Saline, 
Hr- Hour, Ml- Millilitre, PO- Per Oral, Cap- Capsule, RBC- Red Blood 
Cells, WBC- White Blood Cells, APTT- Activated Partial 
Thromboplastin Time, SGPT- Serum Glutamic Pyruvic Transaminase, 
ALT- Alanine Transaminase, AST- Aspartate Aminotransferase, INR- 
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